AR and prostate carcinoma: Moreover, miRNA-130a, acted like a tumor suppressor, has been reported to inhibit the androgen receptor (AR) and mitogen activated protein kinase (MAPK) pathways and target FOS-like antigen 1 (FOSL1) in prostate cancer [19], and triple-negative breast cancer [20], respectively.